Chromadex Corp (CDXC) concluded trading on Wednesday at a closing price of $8.55, with 18.66 million shares of worth about $159.54 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 147.83% during that period and on March 05, 2025 the price saw a gain of about 52.68%. Currently the company’s common shares owned by public are about 76.03M shares, out of which, 48.36M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Stock saw a price change of 51.06% in past 5 days and over the past one month there was a price change of 55.74%. Year-to-date (YTD), CDXC shares are showing a performance of 61.17% which increased to 431.06% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.57 but also hit the highest price of $7.97 during that period. The average intraday trading volume for Chromadex Corp shares is 457.04K. The stock is currently trading 48.53% above its 20-day simple moving average (SMA20), while that difference is up 50.95% for SMA50 and it goes to 94.42% higher than SMA200.
Chromadex Corp (NASDAQ: CDXC) currently have 76.03M outstanding shares and institutions hold larger chunk of about 29.73% of that.
The stock has a current market capitalization of $653.08M and its 3Y-monthly beta is at 2.35. PE ratio of stock for trailing 12 months is 452.38, while it has posted earnings per share of $0.02 in the same period. Its PEG reads 31.33 and has Quick Ratio of 2.35 while making debt-to-equity ratio of 0.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CDXC, volatility over the week remained 12.82% while standing at 6.30% over the month.
Stock’s fiscal year EPS is expected to drop by -25.59% while it is estimated to increase by 51.43% in next year. EPS is likely to shrink at an annualized rate of 14.44% for next 5-years, compared to annual growth of 35.83% made by the stock over the past 5-years.
Coverage by B. Riley Securities stated Chromadex Corp (CDXC) stock as a Neutral in their note to investors on August 11, 2022, suggesting a price target of $2.40 for the stock. On March 08, 2022, ROTH Capital Initiated their recommendations, while on October 16, 2019, Oppenheimer Initiated their ratings for the stock with a price target of $6. Stock get a Buy rating from B. Riley FBR on February 14, 2019.
